Keeping Score of Your Sequence
Twelve months after the debut of the first personal genomics services, Kevin Davies expectorates and explores the pros, cons, and controversies of “23 et al.”
Complete Genomics Targets ‘The First $1000 Genome’
Sequencing service is on track for spring 2009.
Riding Out the Storm
Nothing Ventured | How VCs can survive the current economy.
The Business of Stem Cells
Insights | Outlook | Stem cell research and therapies are poised to be big business.
Grappling with the Next-Gen Data Glut
Storage and data management drain resources even as sequencing speeds up.
Breathing New Life into Old Drugs
ChanTest scours the Orange Book for drug hopefuls.
Tripos’ collaboration with Wyeth enhances research and workflow efficiency.
Clarix Joins Phase Forward
Purchase joins EDC and interactive response technology
Double Layer of Semantics
Flexibility in Translational Research Informatics
BRIDG aims to synchronize CDISC and HL7 semantics.
Tools are becoming increasingly crucial to integrate and analyze translational data.
A Celebration of Spanish Science
BIOSPAIN 2008 encouraged global biotechnology.
Dutch Drug Development Heats Up
A Scandinavian Bridge to Somewhere
Government, academia, and industry stoke the life sciences fires.
Denmark and Sweden focus on personalized medicine and innovative science.
IN EVERY ISSUE
Decoding a Mystery
By Kevin Davies
FIRST BASE | Decode Genetics struggles to define the business plan in Iceland.
Microsoft: Eyes on the LS Enterprise
By John Russell
THE RUSSELL TRANSCRIPT | Microsoft positions itself to make a life sciences play.